Suppr超能文献

多潘立酮通过抑制人肾癌Caki-2细胞中的STAT3信号通路诱导细胞凋亡。

Domperidone Induces Apoptosis through Suppression of STAT3 Signaling in Human Renal Cancer Caki-2 Cells.

作者信息

Park Geumi, Baniya Manoj Kumar, Cha Eun-Jeong, Sim So Jin, Choi Joon-Seok, Chun Kyung-Soo

机构信息

College of Pharmacy, Keimyung University, Daegu, Korea.

Preclinical Research Center, Daegu-Gyeongbuk Medical Innovation Foundation (K-MEDIhub), Daegu, Korea.

出版信息

J Cancer Prev. 2025 Mar 30;30(1):24-31. doi: 10.15430/JCP.24.032.

Abstract

Renal cancer continues to offer a great challenge for its successful therapy today, thus underscoring the need for effective chemotherapeutic agents. In the current study, we explored the anticancer effects of domperidone, a dopamine D2 receptor (DRD2) antagonist, in renal cancer Caki-2 cells. Domperidone induced dose and time-dependent cytotoxic effects in Caki-2 cells, triggering intrinsic apoptosis via the stimulation of the caspase cascade and PARP cleavage. The cytotoxic effect of domperidone was found to be partially DRD2-dependent. Domperidone treatment markedly augmented the production of intracellular reactive oxygen species which induced the cell death of Caki-2 cells. In addition, domperidone suppressed Janus kinase 2 and STAT3 phosphorylation, leading to inhibition of survival and proliferation of these cells. Hence, domperidone can be considered a promising candidate for renal cancer treatment.

摘要

如今,肾癌的成功治疗仍然面临巨大挑战,这凸显了对有效化疗药物的需求。在本研究中,我们探究了多巴胺D2受体(DRD2)拮抗剂多潘立酮对肾癌Caki-2细胞的抗癌作用。多潘立酮在Caki-2细胞中诱导剂量和时间依赖性的细胞毒性作用,通过刺激半胱天冬酶级联反应和PARP裂解引发内源性凋亡。发现多潘立酮的细胞毒性作用部分依赖于DRD2。多潘立酮处理显著增加了细胞内活性氧的产生,从而诱导Caki-2细胞死亡。此外,多潘立酮抑制了Janus激酶2和STAT3的磷酸化,导致这些细胞的存活和增殖受到抑制。因此,多潘立酮可被视为肾癌治疗的一个有前景的候选药物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1aa3/11973461/ae8defb3787d/jcp-30-1-24-f1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验